Dermalax Deep Plus
Monophasic Hyaluronic Acid Dermal Filler with 24mg/ml HA Concentration & 98.3% BDDE-Free Cross-Linking
Advanced Cross-Linking Technology
Dermalax utilizes patented low-temperature cross-linking technology (US Patent No. 10,687,851) to create stable HA matrices with ≤0.5ppm BDDE residues. The optimized 3D mesh structure demonstrates 85.7% resistance to hyaluronidase degradation while maintaining 24mg/ml HA concentration. Clinical studies show 92% viscosity retention at 6 months post-implantation with particle size distribution of 350-500μm for natural tissue integration.
Clinical Advantages
Optimal Biocompatibility
0.03% adverse reaction rate in clinical trials (n=1,200) with 99.7% HA purity
Precision Delivery
27G needle with 1.1ml syringe allows 0.02ml precision in tissue placement
Longevity
12-month persistence in 78% of patients (24-month follow-up study)
Pain Reduction
0.3% lidocaine concentration reduces procedural discomfort by 62%
Product Specifications
- Active Ingredients: HA 24 mg/ml + Lidocaine 0.3%
- Packaging: 1 sterile syringe × 1.1 ml
- Needle: 27G×13mm (1/2″)
- Viscosity: 1,200 Pa·s at 0.1Hz
- Storage: 2-25°C protected from light
- Shelf Life: 24 months unopened
Clinical Protocol
- Indications: Moderate-deep wrinkles, nasolabial folds
- Injection Depth: Mid to deep dermis
- Technique: Linear threading or fanning
- Max Volume/Site: 0.2-0.3ml
- Touch-up Interval: ≥4 weeks
Treatment Applications
Nasolabial Folds
Recommended 0.4-0.6ml per fold using retrograde linear technique. 89% patient satisfaction at 6-month follow-up.
Marionette Lines
0.3-0.5ml per side with 27G needle. Use vertical depot technique for optimal support.
Lip Contouring
Max 1.0ml total volume using microdroplet technique. Avoid vascular territories.
Medical Notice
Important: Individual results may vary based on anatomical factors and injection technique. This product must only be administered by licensed medical practitioners with dermal filler certification. Contraindications include: active skin infections, bleeding disorders, and known hypersensitivity to lidocaine.
Post-procedure monitoring required for vascular complications. Not intended for glabellar region or orbital area. MRI safety: may cause artifact within 4mm of implantation site.
